Role of Macronutrient Diet Composition on Maternal and Infant Metabolic Outcomes

常量营养素饮食成分对母婴代谢结果的作用

• 批准号: 7877696
• 负责人: LINDA Anne BARBOUR
• 金额: $ 22.97万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-20 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7877696
• 关键词: 1-Phosphatidylinositol 3-Kinase; Address; Adipose tissue; Affect; Air; American; Animals; Apolipoproteins B; Area Under Curve; Attenuated; Biological Markers; Biopsy; Birth Weight; Body Composition; C-reactive protein; CCL2 gene; Carbohydrates; Cause of Death; Child; Childhood; Cholesterol; Complex; Consensus; Consumption; Cross-Over Studies; Crossover Design; Data; Development; Diabetes Mellitus; Diagnosis; Diet; Diet therapy; Dietary Fats; Dietary Intervention; Educational workshop; Environment; Epidemic; Erythrocytes; Exposure to; Fat-Restricted Diet; Fatty Liver; Fatty acid glycerol esters; Fetal Growth; Fetal Macrosomia; Fetus; Future; Gene Proteins; Gestational Diabetes; Gluconeogenesis; Glucose; Glucose Intolerance; Goals; Growth; Guidelines; Health; Hour; Human; Hyperglycemia; Hyperlipidemia; Hypertriglyceridemia; IL8 gene; In Vitro; Incidence; Infant; Inflammation; Inflammatory; Insulin; Insulin Resistance; Intake; Interleukin-6; International; Intervention; Isoproterenol; LDL Cholesterol Lipoproteins; Leptin; Life; Lipid Peroxidation; Lipids; Lipolysis; Lipoprotein (a); Lipoproteins; Long-Term Effects; Low-Density Lipoproteins; Macronutrients Nutrition; Measures; Medical; Membrane; Metabolic; Metabolism; Mothers; Neonatal; Newborn Infant; Non-Insulin-Dependent Diabetes Mellitus; Nonesterified Fatty Acids; Nutrient; Obesity; Outcome; Overweight; Phosphatidylinositols; Phosphotransferases; Physiological; Pilot Projects; Plasma; Plethysmography; Pregnancy; Pregnant Women; Prevalence; Proteins; Proxy; Randomized; Randomized Controlled Trials; Recommendation; Research Personnel; Risk; Risk Factors; Risk Marker; Role; Safety; System; Testing; Triglycerides; Woman; adipokines; adiponectin; adverse outcome; apolipoprotein B-100; atherogenesis; base; cholesterol biosynthesis; clinical Diagnosis; cytokine; design; diabetes risk; disorder risk; fetal; fetal programming; glucose monitor; high risk; human data; impaired glucose tolerance; in utero; infant monitoring; inflammatory marker; lipoprotein lipase; neonate; nonhuman primate; novel diagnostics; nutrition; obesity in children; offspring; oxidized low density lipoprotein; particle; prevent; programs; protein expression; public health relevance; randomized trial; resistin; saturated fat; treatment as usual

DESCRIPTION (provided by applicant): Despite the doubling in the prevalence of gestational diabetes mellitus (GDM) over the last 10 years, dietary management guidelines remain ambiguous due to the paucity of randomized controlled trials. New diagnostic criteria recently developed for the diagnosis of GDM are expected to increase the prevalence to 10-15% of all pregnant women. There is growing recognition that GDM has long-term implications on maternal risk for diabetes and that the intrauterine GDM environment is an independent risk factor for childhood obesity and impaired glucose tolerance. Yet, how diet can be used to modify fetal fuel and attenuate this risk remains unknown in humans. Fundamental to the management of GDM is dietary intervention, yet the historic practice of advising a low-carbohydrate (CHO), higher-fat diet has not been sufficiently tested. Both animal and non- human primate data support a fetal programming influence that maternal high-fat diets may promote insulin resistance, glucose intolerance, and hepatic steatosis in the offspring. Recent human data suggest that high maternal triglycerides (TG) and free fatty acids (FFA), variables sensitive to dietary manipulation, are independent risk factors for fetal macrosomia and adiposity. As a result, consensus groups have abandoned any specific diet recommendations for women with GDM. Despite the pivotal role of diet therapy in the treatment of GDM, no randomized trials have directly compared glycemic and lipoprotein profiles of the conventional higher-fat diet with any other diet. To address this critical need, the aims of this randomized cross-over trial are to study the effects of a high complex carbohydrate/low-fat diet (HC/LF; 60% CHO, 25% fat, 15% protein) compared to the usual care, low-CHO/higher fat diet (LC/HF; 40% CHO, 45% fat, and 15% protein) in GDM women on: 1) 72-hour glycemic profiles using a continuous glucose monitoring system within subjects; 2) postprandial lipemia by measuring serial plasma TG and FFA over a 5-hour, post-breakfast meal period within subjects; and 3) maternal lipoproteins, inflammatory profiles, and in-vitro adipose tissue lipolysis after 6-8 weeks of diet therapy between subjects. We will also measure neonatal adiposity by air displacement plethysmography and newborn markers of lipid peroxidation, inflammation, and dietary fat intake in the babies born to mothers with GDM. This pilot study will directly test which GDM diet is most effective in limiting maternal hyperglycemia and hyperlipidemia in a randomized controlled fashion, potentially optimizing fetal substrate availability and fetal growth. Our goal is to determine which diet intervention might favorably impact a cycle that could otherwise perpetuate future diabetes, obesity, and CVD in both mother and offspring. PUBLIC HEALTH RELEVANCE: A better understanding of the optimal diet for women with gestational diabetes is fundamental to the management of this rapidly growing problem in pregnancy. Careful comparison studies of the current low- carbohydrate, higher-fat diet versus a diet higher in complex carbohydrate but lower in fat is critical in order to determine which diet results in a more favorable maternal 24-hour glucose, lipid, and inflammatory profile, all of which directly affect optimal fetal growth and may influence the future health of the offspring.

描述（由申请人提供）：尽管在过去的10年中，妊娠期糖尿病（GDM）的患病率翻了一番，但由于缺乏随机对照试验，饮食管理指南仍然含糊不清。最近开发的用于诊断GDM的新诊断标准预计将使所有孕妇的患病率增加到10-15%。越来越多的人认识到GDM对母体糖尿病风险具有长期影响，宫内GDM环境是儿童肥胖和糖耐量受损的独立危险因素。然而，如何饮食可以用来修改胎儿燃料和减弱这种风险仍然是未知的人类。GDM管理的基础是饮食干预，但建议低碳水化合物（CHO），高脂肪饮食的历史实践尚未得到充分的测试。动物和非人灵长类动物数据均支持胎儿编程影响，即母体高脂肪饮食可能促进后代的胰岛素抵抗、葡萄糖耐受不良和肝脂肪变性。最近的人类数据表明，高母体甘油三酯（TG）和游离脂肪酸（FFA），对饮食控制敏感的变量，是巨大儿和肥胖的独立危险因素。因此，共识小组已经放弃了对GDM女性的任何具体饮食建议。尽管饮食疗法在GDM的治疗中起着关键作用，但没有随机试验直接比较传统高脂饮食与任何其他饮食的血糖和脂蛋白谱。为了解决这一关键需求，本随机交叉试验的目的是研究高复合碳水化合物/低脂饮食的影响（HC/LF; 60% CHO，25%脂肪，15%蛋白质）与常规护理、低CHO/高脂肪饮食相比（LC/HF; 40% CHO，45%脂肪和15%蛋白质）：1）在受试者中使用连续葡萄糖监测系统的72小时血糖曲线; 2）餐后脂血，通过测量受试者早餐后5小时内的连续血浆TG和FFA;和3）受试者之间的母体脂蛋白、炎症特征和6-8周饮食治疗后的体外脂肪组织脂解。我们还将通过空气置换体积描记术和新生儿脂质过氧化、炎症和饮食脂肪摄入的标志物来测量GDM母亲所生婴儿的新生儿肥胖。这项初步研究将直接测试GDM饮食是最有效的限制产妇高血糖症和高脂血症的随机对照的方式，可能优化胎儿底物的可用性和胎儿的生长。我们的目标是确定哪种饮食干预可能会有利地影响一个周期，否则可能会使母亲和后代的未来糖尿病，肥胖和CVD永久化。 公共卫生相关性：更好地了解妊娠期糖尿病女性的最佳饮食对于管理妊娠期这个快速增长的问题至关重要。对当前低碳水化合物、高脂肪饮食与高复合碳水化合物但低脂肪饮食的仔细比较研究至关重要，以确定哪种饮食导致更有利的母体24小时葡萄糖、脂质和炎症特征，所有这些都直接影响最佳胎儿生长并可能影响后代的未来健康。